Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: final results of the randomized, double-blind, placebo-controlled phase II MADONNA study
Abstract Background. This multicenter, double-blind phase II study assessed the antitumor activity and toxicity profile of docetaxel with the antiangiogenic multikinase inhibitor sorafenib or matching placebo as a first-line treatment in patients with metastatic or locally advanced HER2-negative br...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
13 February 2019
|
| In: |
The breast
Year: 2019, Jahrgang: 45, Pages: 22-28 |
| ISSN: | 1532-3080 |
| DOI: | 10.1016/j.breast.2019.02.002 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.breast.2019.02.002
|
| Verfasserangaben: | A. Mavratzas, S. Baek, B. Gerber, M. Schmidt, V. Moebus, F. Foerster, E.M. Grischke, P. Fasching, D. Strumberg, E. Solomayer, P. Klare, C. Windemuth-Kieselbach, S. Hartmann, A. Schneeweiss, F. Marmé |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1671208382 | ||
| 003 | DE-627 | ||
| 005 | 20220816205007.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190812s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.breast.2019.02.002 |2 doi | |
| 035 | |a (DE-627)1671208382 | ||
| 035 | |a (DE-599)KXP1671208382 | ||
| 035 | |a (OCoLC)1341235766 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mavratzas, Athanasios |d 1980- |e VerfasserIn |0 (DE-588)1048709590 |0 (DE-627)781110890 |0 (DE-576)40302644X |4 aut | |
| 245 | 1 | 0 | |a Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer |b final results of the randomized, double-blind, placebo-controlled phase II MADONNA study |c A. Mavratzas, S. Baek, B. Gerber, M. Schmidt, V. Moebus, F. Foerster, E.M. Grischke, P. Fasching, D. Strumberg, E. Solomayer, P. Klare, C. Windemuth-Kieselbach, S. Hartmann, A. Schneeweiss, F. Marmé |
| 264 | 1 | |c 13 February 2019 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.08.2019 | ||
| 520 | |a Abstract Background. This multicenter, double-blind phase II study assessed the antitumor activity and toxicity profile of docetaxel with the antiangiogenic multikinase inhibitor sorafenib or matching placebo as a first-line treatment in patients with metastatic or locally advanced HER2-negative breast cancer. Patients and methods: Patients were randomized 1:1 to receive docetaxel 100mg/m2 on day 1 every 3 weeks in combination with sorafenib 400mg bid or placebo on days 2–18 of each cycle until tumor progression, or unacceptable toxicity. Sorafenib/placebo could be continued at the investigator's discretion if docetaxel was stopped due to toxicity. Primary endpoint was progression free survival (PFS). Results: From October 2008 to December 2013, 102 patients were randomized; 98 patients were evaluable. The trial was prematurely terminated due to slow accrual. Due to increased toxicity the dose of docetaxel was reduced to 75mg/m2 and an increasing sorafenib dosing schedule was implemented as part of a protocol amendment. The addition of sorafenib to docetaxel did not improve PFS (8.2 vs. 7.3 months for docetaxel/placebo; HR 0.84, log rank p=0.43), but led to higher rates of early treatment discontinuation. There were no statistically significant differences between sorafenib dosing schedules. Conclusions: Addition of sorafenib to taxane-based first-line chemotherapy in patients with metastatic breast cancer failed to improve PFS and resulted in increased toxicity. | ||
| 700 | 1 | |a Baek, Sunhwa |d 1983- |e VerfasserIn |0 (DE-588)1153514109 |0 (DE-627)1014951852 |0 (DE-576)500282692 |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The breast |d Amsterdam [u.a.] : Elsevier, 1992 |g 45(2019), Seite 22-28 |h Online-Ressource |w (DE-627)320475042 |w (DE-600)2009043-2 |w (DE-576)103868151 |x 1532-3080 |7 nnas |a Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer final results of the randomized, double-blind, placebo-controlled phase II MADONNA study |
| 773 | 1 | 8 | |g volume:45 |g year:2019 |g pages:22-28 |g extent:7 |a Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer final results of the randomized, double-blind, placebo-controlled phase II MADONNA study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.breast.2019.02.002 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190812 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 910000 |d 910400 |e 910000PM132561972 |e 910400PM132561972 |k 0/910000/ |k 1/910000/910400/ |p 15 |y j | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 14 | ||
| 998 | |g 1153514109 |a Baek, Sunhwa |m 1153514109:Baek, Sunhwa |d 910000 |d 910400 |e 910000PB1153514109 |e 910400PB1153514109 |k 0/910000/ |k 1/910000/910400/ |p 2 | ||
| 998 | |g 1048709590 |a Mavratzas, Athanasios |m 1048709590:Mavratzas, Athanasios |d 910000 |d 910400 |e 910000PM1048709590 |e 910400PM1048709590 |k 0/910000/ |k 1/910000/910400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1671208382 |e 3506512579 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"part":{"extent":"7","year":"2019","pages":"22-28","text":"45(2019), Seite 22-28","volume":"45"},"pubHistory":["1.1992 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"recId":"320475042","disp":"Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer final results of the randomized, double-blind, placebo-controlled phase II MADONNA studyThe breast","title":[{"title_sort":"breast","title":"The breast"}],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; Burlington, Mass.","dateIssuedDisp":"1992-","publisher":"Elsevier ; Harcourt","dateIssuedKey":"1992"}],"id":{"eki":["320475042"],"issn":["1532-3080"],"zdb":["2009043-2"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 27.04.2020","Fortsetzung der Druck-Ausgabe"]}],"id":{"eki":["1671208382"],"doi":["10.1016/j.breast.2019.02.002"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"13 February 2019"}],"person":[{"role":"aut","display":"Mavratzas, Athanasios","given":"Athanasios","roleDisplay":"VerfasserIn","family":"Mavratzas"},{"given":"Sunhwa","display":"Baek, Sunhwa","role":"aut","family":"Baek","roleDisplay":"VerfasserIn"},{"family":"Schneeweiss","roleDisplay":"VerfasserIn","given":"Andreas","role":"aut","display":"Schneeweiss, Andreas"},{"display":"Marmé, Frederik","role":"aut","given":"Frederik","family":"Marmé","roleDisplay":"VerfasserIn"}],"note":["Gesehen am 12.08.2019"],"physDesc":[{"extent":"7 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"name":{"displayForm":["A. Mavratzas, S. Baek, B. Gerber, M. Schmidt, V. Moebus, F. Foerster, E.M. Grischke, P. Fasching, D. Strumberg, E. Solomayer, P. Klare, C. Windemuth-Kieselbach, S. Hartmann, A. Schneeweiss, F. Marmé"]},"title":[{"title":"Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer","subtitle":"final results of the randomized, double-blind, placebo-controlled phase II MADONNA study","title_sort":"Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer"}],"recId":"1671208382"} | ||
| SRT | |a MAVRATZASASORAFENIBI1320 | ||